UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 stock options and sold 9,500 United Therapeutics (UTHR) common shares held via a trust under a 10b5-1 plan on September 4, 2026.

On September 4, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options with a $117.76 strike price and acquired 9,500 shares of common stock, then sold an equal 9,500 shares in a series of open market transactions under a pre-arranged Rule 10b5-1 plan adopted on November 7, 2025. The option exercise (coded M) converted 9,500 options expiring March 15, 2027 into common shares at a cost basis of about $1.12 million, while the subsequent sales (coded S) were executed in multiple tranches between roughly $485.85 and $491.69 per share, generating total proceeds of approximately $4.66 million and representing a net spread of roughly $3.5 million on the exercised options. All reported holdings are indirect through various family trusts and a spouse, and following the transactions the reporting person’s trust still holds a substantial stake exceeding 330,000 United Therapeutics shares (plus additional indirect holdings via other trusts and spouse), indicating these trades are structured as part of ongoing, planned diversification and option monetization rather than a wholesale reduction of exposure.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000136

Alert Tier

6